What is VCEL's market cap?

$2.33B, based on the Nov 4 close of $45.48.

What is VCEL's P/E ratio?

96.2× trailing-twelve-month earnings of $24.22M.

Does Vericel pay a dividend?

No regular cash dividend has been paid in the last year.

How much of VCEL is sold short?

5.2M shares, 11.1% of float, as of Oct 15, 2026.

What sector is VCEL in?

Healthcare, in the Biotechnology industry.

NASDAQ · VCELHealthcareBiotechnology

Vericel Corporation (VCEL)

$45.48+10.68%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$45.28▲ 23.38% in range

Nov 3, 2025Low $29.34 · High $48.31Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Vericel closed at $45.48 on Nov 4, up 10.68%, 5.9% below its 52-week closing high. Volume of 1.8M shares was 3.22× its 20-day average (well above normal).

Split-adjusted performance: +13.6% over one month, +23.7% over six months, +23.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $77.46M, up 22.5% from a year earlier, with a net margin of 2.8%.

Short interest was 5.2M shares at the Oct 15 settlement (11.1% of float, 9.5 days to cover).

Market cap$2.33B51.2M shares

Revenue · quarter$77.5M+22.5% YoY

Diluted EPS$0.04—

P/E · TTM96.2×P/S 7.6×

Net margin2.8%Gross 72.8%

Dividend yieldNone

52-week range29.34 – 48.31−5.9% from high

Volume1.8M3.22× 20-day avg

Volatility · 60d38.8%Annualised

Short % of float11.1%9.5 days to cover

Net cash$162.5MCash $162.5M

Next earnings—Not scheduled

Split-adjusted performance

1W +10.7%1M +13.6%3M +1.6%6M +23.7%YTD +26.3%1Y +23.9%3Y +32.3%5Y −10.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum80

Revenue growth65

Net margin75

Value (low P/E)8

Size80

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short5.2M+0.7% vs prior

Days to cover9.5Settled Oct 15

% of float11.1%

Short vol. 10d64.1%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
VCELVericel	$45.48	+10.68%	+23.7%	+22.5%	2.8%	96.2	$2.33B
RXRXRecursion Pharmaceuticals	$3.88	+5.43%	+13.1%	+258.5%	−641.6%	—	$2.32B	Compare
ADMAADMA Biologics	$10.48	−5.67%	+4.0%	+2.0%	30.4%	13.9	$2.35B	Compare
COAGHemab Therapeutics Holdings	$45.09	+4.62%	—	—	—	—	$2.11B	Compare
BCRXBioCryst Pharmaceuticals	$8.24	−3.85%	−6.7%	+33.6%	35.9%	—	$2.11B	Compare
VIRVir Biotechnology	$11.77	+4.90%	+14.4%	+19582.5%	33.5%	—	$1.99B	Compare
REPLReplimune Group	$20.69	+0.19%	+501.5%	—	—	—	$1.96B	Compare
BEAMBeam Therapeutics	$27.79	+5.54%	−14.1%	−94.2%	−25036.3%	—	$2.87B	Compare
MAZEMaze Therapeutics	$33.38	+3.50%	+26.1%	—	—	—	$1.85B	Compare

News about Vericel

All news →

Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase ProgramGlobeNewswire Inc. · Jul 30, 2026▲ Positive

Quick answers

What does Vericel do?: Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid.
What is VCEL's market cap?: $2.33B, based on the Nov 4 close of $45.48.
What is VCEL's P/E ratio?: 96.2× trailing-twelve-month earnings of $24.22M.
Does Vericel pay a dividend?: No regular cash dividend has been paid in the last year.
How much of VCEL is sold short?: 5.2M shares, 11.1% of float, as of Oct 15, 2026.
What sector is VCEL in?: Healthcare, in the Biotechnology industry.

About Vericel

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

HQ: Burlington, MA398 employeesListed Feb 4, 1997vcel.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology